Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067318 | 0.87 | RXFP1 (0.34) | PTGESMEN1CLK1KMT2AKDM4E | |
| SCHEMBL10067259 | 0.81 | PTGES (0.44) | PTGESKDM4EALDH1A1HPGDJAK2 | |
| SCHEMBL10082885 | 0.80 | RHEB (0.37) | PTGESALDH1A1JAK2CDK4CCND1 | |
| SCHEMBL10067303 | 0.80 | EGFR (0.44) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10067282 | 0.73 | MAP3K14 (0.50) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10067391 | 0.70 | KDM4E (0.45) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10082076 | 0.70 | ALDH1A1 (0.35) | PTGESMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21180305 | 0.69 | SCD (0.47) | PTGESALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL10067256 | 0.69 | MEN1 (0.56) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL10067288 | 0.69 | GABRA1 (0.47) | MEN1KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | PTGES 1934/4885MEN1 2366/4885CLK1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.